This article first appeared on GuruFocus.

Zevra Therapeutics Inc (NASDAQ:ZVRA) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $26.63 million, and the earnings are expected to come in at -$0.04 per share. The full year 2025's revenue is expected to be $101.03 million and the earnings are expected to be $1.19 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 4 Warning Signs with ZVRA.

Is ZVRA fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Zevra Therapeutics Inc (NASDAQ:ZVRA) have increased from $93.40 million to $101.03 million for the full year 2025 and declined from $162.66 million to $155.85 million for 2026 over the past 90 days. Earnings estimates for Zevra Therapeutics Inc (NASDAQ:ZVRA) have increased from $0.76 per share to $1.19 per share for the full year 2025 and declined from $0.62 per share to $0.55 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Zevra Therapeutics Inc's (NASDAQ:ZVRA) actual revenue was $25.88 million, which beat analysts' revenue expectations of $22.54 million by 14.85%. Zevra Therapeutics Inc's (NASDAQ:ZVRA) actual earnings were $1.21 per share, which beat analysts' earnings expectations of $1.11 per share by 9.30%. After releasing the results, Zevra Therapeutics Inc (NASDAQ:ZVRA) was down by 19.81% in one day.

Based on the one-year price targets offered by 5 analysts, the average target price for Zevra Therapeutics Inc (NASDAQ:ZVRA) is $24.00 with a high estimate of $29.00 and a low estimate of $18.00. The average target implies an upside of 135.53% from the current price of $10.19.

Based on GuruFocus estimates, the estimated GF Value for Zevra Therapeutics Inc (NASDAQ:ZVRA) in one year is $37.59, suggesting an upside of 268.89% from the current price of $10.19.

Based on the consensus recommendation from 8 brokerage firms, Zevra Therapeutics Inc's (NASDAQ:ZVRA) average brokerage recommendation is currently 1.8, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.